Cookie Consent by FreePrivacyPolicy.com
Datalog Logo
Free data on 57M+ companies
Home
Company Information for

EVOX THERAPEUTICS LIMITED

MEDAWAR CENTRE 2ND FLOOR EAST BUILDING, ROBERT ROBINSON AVENUE, OXFORD, OXFORDSHIRE, OX4 4HG,
Company Registration Number
10076821
Private Limited Company
Active

Company Overview

About Evox Therapeutics Ltd
EVOX THERAPEUTICS LIMITED was founded on 2016-03-22 and has its registered office in Oxford. The organisation's status is listed as "Active". Evox Therapeutics Limited is a Private Limited Company registered in UNITED KINGDOM with Companies House and the accounts submission requirement is categorised as FULL
  • Annual turnover is £6.5 million or more
  • The balance sheet total is £ 3.26 million or more
  • Employs 50 or more employees
  • May be publically listed
  • May be a member of a group of companies meeting any of the above criteria
Key Data
Company Name
EVOX THERAPEUTICS LIMITED
 
Legal Registered Office
MEDAWAR CENTRE 2ND FLOOR EAST BUILDING
ROBERT ROBINSON AVENUE
OXFORD
OXFORDSHIRE
OX4 4HG
 
Filing Information
Company Number 10076821
Company ID Number 10076821
Date formed 2016-03-22
Country UNITED KINGDOM
Origin Country United Kingdom
Type Private Limited Company
CompanyStatus Active
Lastest accounts 31/12/2022
Account next due 30/09/2024
Latest return 
Return next due 19/04/2017
Type of accounts FULL
VAT Number /Sales tax ID GB247049010  
Last Datalog update: 2024-04-06 17:25:05
Primary Source:Companies House
Is this data useful to you?
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.

Company Officers of EVOX THERAPEUTICS LIMITED

Current Directors
Officer Role Date Appointed
SARAH LUCINDA GORDON WILD
Director 2017-03-15
PER LUNDIN
Director 2016-04-07
ANDREW JAMES MCLEAN
Director 2016-03-22
ANTONIN ROBERT ROLLET DE FOUGEROLLES
Director 2017-10-17
ADAM STOTEN
Director 2016-04-07
MATTHEW JOHN ANDREW WOOD
Director 2016-04-07

Related Directorships

Officer Related Company Role Date Appointed Role StatusIncorporation dateCompany Status
SARAH LUCINDA GORDON WILD OXFORD NANOPORE TECHNOLOGIES PLC Director 2015-01-01 CURRENT 2005-03-09 Active
SARAH LUCINDA GORDON WILD LEWESTON SCHOOL TRUST Director 2013-11-27 CURRENT 1986-07-28 Active
SARAH LUCINDA GORDON WILD SGW RESEARCH LIMITED Director 2003-02-10 CURRENT 2002-07-10 Active
ANDREW JAMES MCLEAN IRREVERENT COMPANY LIMITED Director 2018-04-11 CURRENT 2018-04-11 Active
ANDREW JAMES MCLEAN PEPGEN LIMITED Director 2018-03-26 CURRENT 2018-01-25 Active
ANDREW JAMES MCLEAN THEOLYTICS LTD Director 2017-12-19 CURRENT 2017-10-06 Active
ANDREW JAMES MCLEAN DJS ANTIBODIES LTD Director 2016-10-05 CURRENT 2014-07-21 Active
ANDREW JAMES MCLEAN OSLER DIAGNOSTICS LIMITED Director 2016-06-21 CURRENT 2016-02-11 Active
ANDREW JAMES MCLEAN ARGONAUT THERAPEUTICS LIMITED Director 2016-04-14 CURRENT 2016-02-08 Active
ANDREW JAMES MCLEAN BARINTHUS BIOTHERAPEUTICS (UK) LIMITED Director 2016-01-27 CURRENT 2016-01-27 Active
ADAM STOTEN BARINTHUS BIOTHERAPEUTICS (UK) LIMITED Director 2016-03-04 CURRENT 2016-01-27 Active
ADAM STOTEN BROADBRIDGE BIOTECH LTD Director 2013-05-29 CURRENT 2013-05-29 Dissolved 2015-06-09
MATTHEW JOHN ANDREW WOOD PEPGEN LIMITED Director 2018-03-26 CURRENT 2018-01-25 Active
MATTHEW JOHN ANDREW WOOD GMEC MANAGEMENT COMPANY LIMITED Director 2017-02-15 CURRENT 2008-11-26 Active - Proposal to Strike off
MATTHEW JOHN ANDREW WOOD MEDCITY LTD Director 2016-10-06 CURRENT 2013-11-27 Active
MATTHEW JOHN ANDREW WOOD OXFORD UNIVERSITY INNOVATION LIMITED Director 2015-06-29 CURRENT 1987-11-27 Active

More director information

Corporation Filing History
Companies House Filing History
This is a record of the public documents (corporate filing) lodged from Companies House where the company has filed annual returns and other statutory filing documents. Examples of documents filed include: change of registered office, accounts filing, director/officer appointments & resignations, changes in share capital, shareholder members lists etc.

DateDocument TypeDocument Description
2024-05-09APPOINTMENT TERMINATED, DIRECTOR ANTONIN ROBERT ROLLET DE FOUGEROLLES
2024-05-09DIRECTOR APPOINTED DR PER LUNDIN
2024-05-09APPOINTMENT TERMINATED, DIRECTOR PAUL RUTHERFORD CARTER
2024-03-28CONFIRMATION STATEMENT MADE ON 16/03/24, WITH NO UPDATES
2024-01-25Director's details changed for Mr Martin Andrews on 2020-11-01
2024-01-25Director's details changed for Amrit Nagpal on 2022-07-01
2023-10-03APPOINTMENT TERMINATED, DIRECTOR JOHN GEORGE MCHUTCHISON
2023-10-03DIRECTOR APPOINTED MR ALEXANDER ERIC HAMMACHER
2023-08-17REGISTERED OFFICE CHANGED ON 17/08/23 FROM Medawar Centre 2nd Floor, East Building Robert Robinson Avenue Oxford Oxfordshire OX4 4GA England
2023-06-27FULL ACCOUNTS MADE UP TO 31/12/22
2023-03-29CONFIRMATION STATEMENT MADE ON 16/03/23, WITH UPDATES
2022-10-0501/09/22 STATEMENT OF CAPITAL GBP 10133.12
2022-07-07AAFULL ACCOUNTS MADE UP TO 31/12/21
2022-05-19SH0104/05/22 STATEMENT OF CAPITAL GBP 10132.17
2022-05-19AP01DIRECTOR APPOINTED DR EVAN SAMUEL CAPLAN
2022-03-30CS01CONFIRMATION STATEMENT MADE ON 16/03/22, WITH UPDATES
2022-03-21PSC05Change of details for Oxford Sciences Innovation Plc as a person with significant control on 2021-09-30
2022-03-17TM01APPOINTMENT TERMINATED, DIRECTOR CHAU Q. KHUONG
2022-02-28SH0127/01/22 STATEMENT OF CAPITAL GBP 10131.92
2022-01-2612/01/22 STATEMENT OF CAPITAL GBP 10131.67
2022-01-26SH0112/01/22 STATEMENT OF CAPITAL GBP 10131.67
2021-09-15SH0116/07/21 STATEMENT OF CAPITAL GBP 10131.57
2021-09-14SH0101/07/21 STATEMENT OF CAPITAL GBP 10130.82
2021-07-04AASMALL COMPANY ACCOUNTS MADE UP TO 31/12/20
2021-06-16CH01Director's details changed for Dr per Lundin on 2020-12-21
2021-04-16CS01CONFIRMATION STATEMENT MADE ON 16/03/21, WITH UPDATES
2021-03-29CH01Director's details changed for Dr Antonin Robert Rollet De Fougerolles on 2020-04-29
2021-03-26SH0125/02/21 STATEMENT OF CAPITAL GBP 10130.32
2021-03-25RES10Resolutions passed:
  • Resolution of allotment of securities
  • Resolution of adoption of Articles of Association
2021-03-25MEM/ARTSARTICLES OF ASSOCIATION
2021-03-12AP01DIRECTOR APPOINTED CHAU Q. KHUONG
2021-03-09TM01APPOINTMENT TERMINATED, DIRECTOR MATTHEW JOHN ANDREW WOOD
2021-01-18AP01DIRECTOR APPOINTED JOHN GEORGE MCHUTCHISON
2020-11-05PSC05Change of details for Oxford Sciences Innovation Plc as a person with significant control on 2019-07-24
2020-08-17AP01DIRECTOR APPOINTED MR MARTIN ANDREWS
2020-08-17AP01DIRECTOR APPOINTED MR MARTIN ANDREWS
2020-07-15AASMALL COMPANY ACCOUNTS MADE UP TO 31/12/19
2020-07-01TM01APPOINTMENT TERMINATED, DIRECTOR ANDREW JAMES MCLEAN
2020-04-23AP01DIRECTOR APPOINTED MR PAUL RUTHERFORD CARTER
2020-03-30TM01APPOINTMENT TERMINATED, DIRECTOR EDWIN MOSES
2020-03-19CS01CONFIRMATION STATEMENT MADE ON 16/03/20, WITH UPDATES
2019-08-01AASMALL COMPANY ACCOUNTS MADE UP TO 31/12/18
2019-03-28CS01CONFIRMATION STATEMENT MADE ON 16/03/19, WITH UPDATES
2019-03-27CH01Director's details changed for Per Lundin on 2016-04-07
2019-03-27PSC05Change of details for Oxford Sciences Innovation Plc as a person with significant control on 2018-08-31
2019-03-22TM01APPOINTMENT TERMINATED, DIRECTOR ADAM STOTEN
2019-02-26CH01Director's details changed for Dr Edwin Moses on 2019-02-08
2019-02-15AP01DIRECTOR APPOINTED AMRIT NAGPAL
2018-10-01SH0131/08/18 STATEMENT OF CAPITAL GBP 6343.77
2018-10-01AA31/12/17 ACCOUNTS TOTAL EXEMPTION FULL
2018-09-17RES10Resolutions passed:
  • Resolution of allotment of securities
  • Resolution of removal of pre-emption rights
  • Resolution of adoption of Articles of Association
2018-04-30AD01REGISTERED OFFICE CHANGED ON 30/04/18 FROM King Charles House Park End Street Oxford Oxfordshire OX1 1JD
2018-03-28CS01CONFIRMATION STATEMENT MADE ON 16/03/18, WITH NO UPDATES
2018-03-28AP01DIRECTOR APPOINTED DR ANTONIN ROBERT ROLLET DE FOUGEROLLES
2017-10-11AP01DIRECTOR APPOINTED MRS SARAH LUCINDA GORDON WILD
2017-10-07AA31/12/16 ACCOUNTS TOTAL EXEMPTION FULL
2017-03-16LATEST SOC16/03/17 STATEMENT OF CAPITAL;GBP 3244.96
2017-03-16CS01CONFIRMATION STATEMENT MADE ON 16/03/17, WITH UPDATES
2016-10-02AD01REGISTERED OFFICE CHANGED ON 02/10/16 FROM The Weston Library Broad Street Oxford Oxfordshire OX1 3BG United Kingdom
2016-09-05AA01Current accounting period shortened from 31/03/17 TO 31/12/16
2016-04-27RES13SECTION 175 COMP ACT, INVESTMENT AGREEMENT 07/04/2016
2016-04-27RES01ADOPT ARTICLES 27/04/16
2016-04-27RES10Resolutions passed:
  • Resolution of allotment of securities
2016-04-19LATEST SOC19/04/16 STATEMENT OF CAPITAL;GBP 3244.96
2016-04-19SH0107/04/16 STATEMENT OF CAPITAL GBP 3244.96
2016-04-14AP01DIRECTOR APPOINTED PROFESSOR MATTHEW JOHN ANDREW WOOD
2016-04-14AP01DIRECTOR APPOINTED DR ADAM STOTEN
2016-04-14AP01DIRECTOR APPOINTED PER LUNDIN
2016-03-22NEWINCCERTIFICATE OF INCORPORATION GENERAL COMPANY DETAILS & STATEMENTS OF; OFFICERS, CAPITAL & SHAREHOLDINGS, GUARANTEE, COMPLIANCE MEMORANDUM OF ASSOCIATION ARTICLES OF ASSOCIATION
Industry Information
SIC/NAIC Codes
72 - Scientific research and development
721 - Research and experimental development on natural sciences and engineering
72110 - Research and experimental development on biotechnology




Licences & Regulatory approval
We could not find any licences issued to EVOX THERAPEUTICS LIMITED or authorisation from an industry specific regulator to operate. These may not be required.
Share this page on Facebook
Risks
Legal Notices
No legal notices or events such as winding-up orders or proposals to strike-off have been issued
Fines / Sanctions
No fines or sanctions have been issued against EVOX THERAPEUTICS LIMITED
Liabilities
Mortgages / Charges
Total # Mortgages/Charges 0
Mortgages/Charges outstanding 0
Mortgages Partially Satisifed 0
Mortgages Satisfied/Paid 0
Details of Mortgagee Charges
EVOX THERAPEUTICS LIMITED does not have any mortgage charges so there is no mortgagee data available

  Average Max

This shows the max and average number of mortgages for companies with the same SIC code of 72110 - Research and experimental development on biotechnology

Intangible Assets
Patents
We have not found any records of EVOX THERAPEUTICS LIMITED registering or being granted any patents
Domain Names
We do not have the domain name information for EVOX THERAPEUTICS LIMITED
Trademarks

Trademark applications by EVOX THERAPEUTICS LIMITED

EVOX THERAPEUTICS LIMITED is the Original Applicant for the trademark e ™ (WIPO1346943) through the WIPO on the 2017-01-15
Pharmaceuticals; pharmaceutical preparations and substances; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; medicine; medical preparations and articles; biological preparations for medical purposes; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosome for pharmaceutical purposes; biological preparations comprising a therapeutic target protein-loaded exosome; biological preparations comprising exosome for use in the manufacture of pharmaceuticals; biological reagents for medical use; mixed biological preparations for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, ev-based nucleic acid therapeutics for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy.
Produits pharmaceutiques; substances et préparations pharmaceutiques; préparations pharmaceutiques, à savoir systèmes de délivrance de substances médicamenteuses comprenant des exosomes génétiquement conçus ou purifiés à usage thérapeutique; préparations pharmaceutiques, à savoir exosomes pour la délivrance de protéines pour thérapies géniques; médicaments; préparations et articles médicaux; préparations biologiques à usage médical; préparations biologiques pour le traitement du cancer, du diabète, de l'obésité, du syndrome métabolique, de la démence et d'autres pathologies associées au vieillissement telles que les maladies mitochondriales, les déchirures/ruptures des articulations/ligaments, l'atrophie musculaire, la dystrophie musculaire; préparations biologiques comprenant un exosome à usage pharmaceutique; préparations biologiques comprenant un exosome chargé de protéines à usage thérapeutique; préparations biologiques comprenant un exosome utilisé dans la fabrication de produits pharmaceutiques; réactifs biologiques à usage médical; préparations biologiques mélangées à usage médical; préparations biologiques mélangées pour la prévention et le traitement de maladies infectieuses; réactifs de diagnostic utilisés dans les domaines de la recherche biologique, pharmaceutique et relative au génie génétique; réactifs de diagnostic comprenant un exosome utilisé dans les domaines de la recherche biologique, pharmaceutique et relative au génie génétique; produits pharmaceutiques, médicaments, produits biologiques, produits biothérapeutiques, produits biologiques ultérieurs et produits thérapeutiques, à savoir produits thérapeutiques d'acides nucléiques basés sur des EV pour la prévention et le traitement d'infections ou de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical pour le test de liquides organiques pour la détection de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical pour le test d'exosomes pour la détection de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical testant la présence du cancer, du diabète, de l'obésité, du syndrome métabolique, de la démence et d'autres pathologies associées au vieillissement telles que les maladies mitochondriales, les déchirures/ruptures des articulations/ligaments, l'atrophie musculaire, la dystrophie musculaire.
Productos farmacéuticos; preparaciones y sustancias farmacéuticas; preparaciones farmacéuticas, a saber, sistemas de administración de medicamentos que contienen exosomas manipulados genéticamente o purificados para uso terapéutico; preparaciones farmacéuticas, a saber, exosomas para administrar proteínas para terapias genéticas; medicamentos; preparaciones y artículos medicinales; preparaciones biológicas para uso médico; preparaciones biológicas para el tratamiento del cáncer, la diabetes, la obesidad, el síndrome metabólico, la demencia y otras patologías asociadas al envejecimiento, tales como enfermedades mitocondriales, sobrecargas y desgarros de articulaciones y ligamentos, atrofias musculares y distrofias musculares; preparaciones biológicas que contienen exosomas para uso farmacéutico; preparaciones biológicas que contienen exosomas cargadas de proteínas con objetivos terapéuticos; preparaciones biológicas que contienen exosomas para la elaboración de productos farmacéuticos; reactivos biológicos para uso médico; preparaciones biológicas combinadas para uso médico; preparaciones biológicas mezcladas para el tratamiento y la prevención de enfermedades infecciosas; reactivos de diagnóstico utilizados en los ámbitos biológicos, de la ingeniería genética y de la investigación farmacéutica; reactivos de diagnóstico que contienen exosomas utilizados en los ámbitos biológicos, de la ingeniería genética y de la investigación farmacéutica; productos farmacéuticos, medicamentos, productos biológicos, productos bioterapéuticos, medicamentos biosimilares y productos terapéuticos, a saber, productos terapéuticos de ácido nucleico a base de VE para la prevención y el tratamiento de infecciones o enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de fluidos corporales para la detección de enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de exosomas para la detección de enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de presencia de cáncer, diabetes, obesidad, síndrome metabólico, demencia, y otras patologías asociadas al envejecimiento, tales como enfermedades mitocondriales, sobrecargas y desgarros de articulaciones y ligamentos, atrofias musculares y distrofias musculares.
EVOX THERAPEUTICS LIMITED is the Original Applicant for the trademark EVOX THERAPEUTICS ™ (WIPO1348112) through the WIPO on the 2016-12-15
Pharmaceuticals; pharmaceutical preparations and substances; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; medicine; medical preparations and articles; biological preparations for medical purposes; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosome; biological preparations comprising a therapeutic target protein-loaded exosome; biological preparations comprising exosome for pharmaceutical purposes; biological reagents for medical use; mixed biological preparations for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutics for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy.
Produits pharmaceutiques; substances et préparations pharmaceutiques; préparations pharmaceutiques, à savoir systèmes de délivrance de substances médicamenteuses comprenant des exosomes génétiquement conçus ou purifiés à usage thérapeutique; préparations pharmaceutiques, à savoir exosomes pour la délivrance de protéines pour thérapies géniques; médicaments; préparations et articles médicaux; préparations biologiques à usage médical; préparations biologiques pour le traitement du cancer, du diabète, de l'obésité, du syndrome métabolique, de la démence et d'autres pathologies associées au vieillissement telles que les maladies mitochondriales, les déchirures/ruptures des articulations/ligaments, l'atrophie musculaire, la dystrophie musculaire; préparations biologiques comprenant un exosome; préparations biologiques comprenant un exosome chargé de protéines à usage thérapeutique; préparations biologiques comprenant un exosome à usage pharmaceutique; réactifs biologiques à usage médical; préparations biologiques mélangées à usage médical; préparations biologiques mélangées pour la prévention et le traitement de maladies infectieuses; réactifs de diagnostic utilisés dans les domaines de la recherche biologique, pharmaceutique et relative au génie génétique; réactifs de diagnostic comprenant un exosome utilisé dans les domaines de la recherche biologique, pharmaceutique et relative au génie génétique; produits pharmaceutiques, médicaments, produits biologiques, produits biothérapeutiques, produits biologiques ultérieurs et produits thérapeutiques, à savoir produits thérapeutiques d'acides nucléiques basés sur des EV pour la prévention et le traitement d'infections ou de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical pour le test de liquides organiques pour la détection de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical pour le test d'exosomes pour la détection de maladies; kits de diagnostic comprenant des réactifs et épreuves de diagnostic médical testant la présence du cancer, du diabète, de l'obésité, du syndrome métabolique, de la démence et d'autres pathologies associées au vieillissement telles que les maladies mitochondriales, les déchirures/ruptures des articulations/ligaments, l'atrophie musculaire, la dystrophie musculaire.
Productos farmacéuticos; preparaciones y sustancias farmacéuticas; preparaciones farmacéuticas, a saber, sistemas de administración de medicamentos que contienen exosomas purificados o manipulados genéticamente para uso terapéutico; preparaciones farmacéuticas, a saber, exosomas para administrar proteínas para terapias genéticas; medicamentos; preparaciones y artículos medicinales; preparaciones biológicas para uso médico; preparaciones biológicas para el tratamiento del cáncer, la diabetes, la obesidad, el síndrome metabólico, la demencia y otras patologías asociadas al envejecimiento, tales como enfermedades mitocondriales, sobrecargas y desgarros de articulaciones y ligamentos, atrofias musculares y distrofias musculares; preparaciones biológicas que contienen exosomas; preparaciones biológicas que contienen exosomas cargadas de proteínas con objetivos terapéuticos; preparaciones biológicas que contienen exosomas para uso farmacéutico; reactivos biológicos para uso médico; preparaciones biológicas combinadas para uso médico; preparaciones biológicas mezcladas para el tratamiento y la prevención de enfermedades infecciosas; reactivos de diagnóstico utilizados en los ámbitos de la biología, la ingeniería genética y la investigación farmacéutica; reactivos de diagnóstico que contienen exosomas utilizados en los ámbitos de la biología, la ingeniería genética y la investigación farmacéutica; productos farmacéuticos, medicamentos, productos biológicos, productos bioterapéuticos, medicamentos biosimilares y productos terapéuticos, a saber, productos terapéuticos de ácido nucleico a base de VE para la prevención y el tratamiento de infecciones o enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de fluidos corporales para la detección de enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de exosomas para la detección de enfermedades; kits de diagnóstico compuestos de reactivos y ensayos de diagnóstico médico para la prueba de presencia de cáncer, diabetes, obesidad, síndrome metabólico, demencia, y otras patologías asociadas al envejecimiento, tales como enfermedades mitocondriales, sobrecargas y desgarros de articulaciones y ligamentos, atrofias musculares y distrofias musculares.
Income
Government Income
We have not found government income sources for EVOX THERAPEUTICS LIMITED. This could be because the transaction value was below £ 500 with local government or below £ 25,000 for central government. We have found 8,000 supplier to government that are UK companies so approx 0.2% of companies listed on Datalog supply to government.

The top companies supplying to UK government with the same SIC code (72110 - Research and experimental development on biotechnology) as EVOX THERAPEUTICS LIMITED are:

Outgoings
Business Rates/Property Tax
No properties were found where EVOX THERAPEUTICS LIMITED is liable for the business rates / property tax. This could be for a number of reasons.
  • The council hasnt published the data
  • We havent found or been able to process the councils data
  • The company is part of a group of companies and another company in the group is liable for business rates
  • The registered office may be a residential address which does not have a commercial designation. If the business is run from home then it won't be a commercial property and hence won't be liable for business rates.
  • Serviced offices are increasingly popular and therefore a business may not be paying business rates directly - the building owner is and this is incorporated in the office rental charge.
Import/Export of Goods
Goods imported/exported by EVOX THERAPEUTICS LIMITED
OriginDestinationDateImport CodeImported Goods classification description
2018-12-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-12-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-11-0030021200
2018-11-0030021200
2018-11-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-11-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-11-0085439000Parts of electrical machines and apparatus, having individual functions, n.e.s. in chapter 85
2018-11-0085439000Parts of electrical machines and apparatus, having individual functions, n.e.s. in chapter 85
2018-10-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)
2018-10-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)
2018-09-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-09-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-06-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-06-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-05-0071131900Articles of jewellery and parts thereof, of precious metal other than silver, whether or not plated or clad with precious metal (excl. articles > 100 years old)
2018-05-0071131900Articles of jewellery and parts thereof, of precious metal other than silver, whether or not plated or clad with precious metal (excl. articles > 100 years old)
2018-04-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-04-0038220000Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2018-04-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)
2018-04-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)
2018-03-0029299000Compounds with nitrogen function (excl. amine-function compounds; oxygen-function amino-compounds; quaternary ammonium salts and hydroxides; lecithin and other phosphoaminolipids; carboxyamide-function compounds; amide-function compounds of carbonic acid; carboxyimide-function, imine-function or nitrile-function compounds; diazo-, azo- or azoxy-compounds; organic derivatives of hydrazine or of hydroxylamine and isocyanates)
2018-03-0029299000Compounds with nitrogen function (excl. amine-function compounds; oxygen-function amino-compounds; quaternary ammonium salts and hydroxides; lecithin and other phosphoaminolipids; carboxyamide-function compounds; amide-function compounds of carbonic acid; carboxyimide-function, imine-function or nitrile-function compounds; diazo-, azo- or azoxy-compounds; organic derivatives of hydrazine or of hydroxylamine and isocyanates)
2018-01-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)
2018-01-0084798200Mixing, kneading, crushing, grinding, screening, sifting, homogenising, emulsifying or stirring machines, n.e.s. (excl. industrial robots)

For goods imported into the United Kingdom, only imports originating from outside the EU are shown

Government Grants / Awards
Technology Strategy Board Awards
The Technology Strategy Board has not awarded EVOX THERAPEUTICS LIMITED any grants or awards. Grants from the TSB are an indicator that the company is investing in new technologies or IPR
European Union CORDIS Awards
The European Union has not awarded EVOX THERAPEUTICS LIMITED any grants or awards.
Ownership
    We could not find any group structure information
    Is this data useful to you?
    If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
    Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.
    Need more information?
    We offer bespoke investigations into companies. If you need more information about this company we can gather more information as directed by you. This may, for example, be a forensic investigation such as tracing hidden assets. The engagement is on a time and materials basis. We charge GBP £ 500 per day + VAT. Contact us with a description of what you're looking for and we will assess whether we can help.
    Other companies at postcode OX4 4HG